“We made meaningful progress in the quarter advancing our clinical trials for Tinlarebant and are excited by our results,” said Dr. Tom Lin, Chairman and CEO of Belite Bio. “Results from our Phase 2 trial of Tinlarebant in childhood-onset Stargardt Disease showed Tinlarebant lowered retinal lesion growth versus patients in a 24-month natural history study and visual acuity was stabilized, all while remaining safe and well-tolerated. Additionally, in the quarter, we completed enrollment for the DRAGON trial, dosed our first subject and made substantial progress in the PHOENIX trial. We remain focused on our vision to bring novel therapies to patients suffering from degenerative retinal diseases.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BLTE:
- Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results
- Is BLTE a Buy, Before Earnings?
- Belite Bio participates in a conference call with Cantor Fitzgerald
- Belite Bio price target raised to $59 from $55 at H.C. Wainwright
- Belite Bio presents results from a 24-month, Phase 2 study of Tinlarebant
